Volume | 89 890 |
|
|||||
Actualités | (1) | ||||||
Maximum Haut | 3,3299 | Bas Haut |
|||||
Minimum Bas | 3,12 |
Nom Action | Symbole Action | Marché | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Action ordinaire |
Ouverture | Plus Bas | Plus Haut | Prix de clôture | Clôture Veille |
---|---|---|---|---|
3,26 | 3,12 | 3,3299 | 3,155 | 3,28 |
Transactions Totales | Volume échangé | VWAP | Volume Financier | Volume en moyenne | Sur 52 semaines |
---|---|---|---|---|---|
630 | 89 890 | US$ 3,21 | US$ 288 128 | - | 2,9539 - 14,37 |
Dernière Transaction | Type | Quantités échangées | Prix transaction | Devise |
---|---|---|---|---|
01:23:54 | 10 | US$ 3,23 | USD |
Bilan Comptable
Capitalisation Boursière | Actions en Circulation | Float | Chiffre d'affaires | Bénéfice/Perte | BPA | Ratio Cours sur Bénéfices |
---|---|---|---|---|---|---|
4,32M | 1,38M | - | 0 | -7,6M | -5,50 | - |
Short Interest | Dividendes Par Action | Rendement du Dividende | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
plus d’informations financières »
Actualités Action GT Biopharma
Date | Heure | Source | Titre |
---|---|---|---|
07/6/2024 | 23:25 | Edgar (US Regulatory) | Form 8-K - Current report |
24/5/2024 | 02:31 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
23/5/2024 | 12:04 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
23/5/2024 | 12:02 | Edgar (US Regulatory) | Form 8-K - Current report |
15/5/2024 | 23:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
14/2/2024 | 20:46 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
01/2/2024 | 18:15 | Edgar (US Regulatory) | Form 8-K - Current report |
21/12/2023 | 21:30 | Edgar (US Regulatory) | Form 8-K - Current report |
04/12/2023 | 23:00 | Edgar (US Regulatory) | Form 8-K - Current report |
06/11/2023 | 23:25 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
06/11/2023 | 23:23 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
06/11/2023 | 23:21 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
Forum Action GT Biopharma
Aucune Discussion TrouvéeAjouter une Discussion
Historiques GT Biopharma Inc
Période | Ouver. | Haut | Bas | VWAP | Moyenne Vol. Quot. | Variation | % |
---|---|---|---|---|---|---|---|
1 semaine | 3,88 | 3,88 | 3,12 | 3,46 | 45 359 | -0,78 | -20,10% |
1 mois | 3,30 | 10,6599 | 3,02 | 7,24 | 4 497 467 | -0,20 | -6,06% |
3 mois | 4,55 | 10,6599 | 2,9539 | 7,23 | 1 480 189 | -1,45 | -31,87% |
6 mois | 7,497 | 10,6599 | 2,9539 | 7,20 | 740 432 | -4,40 | -58,65% |
1 an | 8,61 | 14,37 | 2,9539 | 7,72 | 526 202 | -5,51 | -64,00% |
3 ans | 498,00 | 591,993 | 2,9539 | 71,03 | 307 709 | -494,90 | -99,38% |
5 ans | 165,00 | 591,993 | 2,9539 | 109,95 | 338 986 | -161,90 | -98,12% |